Cancer Drug Parity Act of 2025 aims to ensure cost-sharing for oral anticancer drugs is no less favorable than for injectable drugs.
The Cancer Drug Parity Act of 2025 amends the Employee Retirement Income Security Act of 1974 to require group health plans to provide cost-sharing for oral anticancer drugs on terms no less favorable than for injectable drugs. This applies to medications prescribed for medically necessary treatment of cancer. The Act prohibits plans from imposing prior authorization or other controls on coverage for chemotherapy and cannot increase out-of-pocket costs for anticancer medications. The Government Accountability Office must study the impact of these changes and report to Congress.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.